We develop innovative medicines that greatly improve health outcomes for patients with an unremitting focus on quality and affordability. We work with all the top 10 generic pharmaceutical companies in the world. We sell our APIs in 56 countries. Our major focus areas include anti-retroviral, Hepatitis C and Oncology drugs. Continuous innovation is the lifeblood of our business. Therefore, we undertake dedicated R&D in areas that have significant growth potential. We filed 322 patents in which we own 184 patents. We have commercialised 60+ products since inception across three distinct business units: Generics API, Generics FDF and Synthesis. As a company, we conduct our business with utmost transparency and integrity. This helps us attract the best talent and win the trust of our stakeholders. Given that we operate in a highly regulated sector, we adopt a high-watermark approach to compliance to ensure that we exceed the requirements of all applicable international standards.